Last reviewed · How we verify
NCT05091437: DOuBLED
DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis
trial testing Observational study in Pulmonary Nodules in 562 participants. Completed in 30 November 2024.
30 November 2024
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 562 |
| Start date | 30 December 2021 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 14 locations across Panama, Colombia, Costa Rica, Dominican Republic, Chile, Mexico, Argentina, Brazil |
Drugs / interventions tested
- Observational study — full drug profile →
Conditions studied
- Pulmonary Nodules — all drugs for Pulmonary Nodules →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 35 to 100, any sex, with Pulmonary Nodules. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early diagnosis of LC in the asymptomatic stage through intentional screening programs and/or incidental pulmonary nodule identification and follow-up are known to improve outcomes significantly. There are large gaps in the screening and early detection of LC, especially in LMIC - driven by multifactorial aspects, including a variety of socioeconomic and infrastructural factors, mainly due to limitations in the required network of specialized human resources and technical capacity. Identifying LC at an early stage allows for treatment that is more likely to be curative, thereby improving survival. The present study aims to characterize the lung nodule journey in different hospitals/clinics across Latin America, describing the use of health resources, time to diagnosis, stage at diagnosis, and time to treatment depending on the source of nodule identification in two different cohorts (retrospective and prospective).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05091437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational study
Trials testing the same drug.
- NCT07255443 — Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital · not yet recruiting
- NCT07343713 — Correlation Between the Degree of Middle Ear Pressure and the Eustachian Tube Dimensions : Radiological Study · not yet recruiting
- NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
- NCT07219927 — Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: · recruiting
- NCT06244238 — A Study on the Relationship Between Job Satisfaction and Retention Intentions of Emergency Room Nurses · unknown
Other recruiting trials for Pulmonary Nodules
Currently open trials in the same condition.
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07153263 — Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block · NA · recruiting
- NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
- NCT06676956 — The SEQUENCE Trial: Evaluating Diagnostic Yield of Robotic-assisted Bronchoscopy When Staging EBUS is Performed First or · NA · recruiting
- NCT07360145 — Intelligent Support for Radiological Reporting of Lung Neoplasms · active not recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05091437 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05091437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing